MAAS Method (Minimal-flow Auto-control Anesthesia System) for the Administration of Desflurane and Sevoflurane
Launched by FUNDACIÓN PÚBLICA ANDALUZA PARA LA GESTIÓN DE LA INVESTIGACIÓN EN SEVILLA · Aug 22, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The MAAS Method clinical trial is looking at a new way to deliver anesthesia during certain types of surgeries, specifically using two anesthetic gases called sevoflurane and desflurane. The goal is to see how accurately a special device called the Minimal-flow Autocontrol Anesthesia System can provide the right amount of these gases to keep patients comfortable and safe while they are under anesthesia. Researchers will monitor how many times adjustments need to be made to keep the levels of anesthesia steady and will also check how long it takes to reach the desired levels.
To be part of this study, participants must be adults scheduled for specific robotic surgeries and must provide written consent. However, certain health conditions, such as severe lung disease or heart issues, may exclude individuals from participating. Those who join the trial can expect to receive tailored care during their procedure, focused on maintaining their lung function. Your participation will help researchers better understand how to improve anesthesia delivery for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult subjects (≥ 18 years) scheduled for robotic urological, coloproctological or gynecological surgery in the investigators´ institution
- • Written informed consent
- Exclusion Criteria:
- • Participation in another interventional study
- • Participants unable to understand the information contained in the informed consent
- • American Society of Anesthesiologists (ASA) classification grade = IV
- • Patient in dialysis
- • Chronic obstructive pulmonary disease (COPD) grade Global Initiative for Chronic Obstructive Lung Disease(GOLD) \> 2
- • Functional vital capacity \< 60% or \> 120% of the predicted
- • Body mass index (BMI) \> 35 kg/m2
- • New York Heart Association (NYHA) functional class ≥ 3
- • Clinically suspected heart failure
- • Diagnosis or suspicion of intracranial hypertension
- • Presence of pneumothorax or giant bullae on preoperative imaging tests
- • Use of Continuous Positive Airway Pressure (CPAP).
About Fundación Pública Andaluza Para La Gestión De La Investigación En Sevilla
The Fundación Pública Andaluza para la Gestión de la Investigación en Sevilla is a public foundation dedicated to advancing clinical research and innovation within the Andalusian healthcare system. By fostering collaboration among healthcare professionals, researchers, and institutions, the foundation aims to enhance the quality and efficiency of clinical trials. With a strong focus on ethical standards and regulatory compliance, it plays a pivotal role in supporting the development of new therapies and improving patient outcomes in the region. Through its commitment to scientific excellence and community health, the foundation contributes significantly to the advancement of medical knowledge and practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sevilla, , Spain
Patients applied
Trial Officials
Manuel de la Matta, PhD
Principal Investigator
Hospitales Universitarios Virgen del Rocío
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials